HomeHROW • NASDAQ
Harrow Inc
$13.23
After Hours:
$13.50
(2.04%)+0.27
Closed: Mar 28, 7:38:43 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$12.73
Day range
$12.70 - $13.48
Year range
$7.60 - $28.25
Market cap
467.85M USD
Avg Volume
537.48K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
36.36M78.83%
Operating expense
29.55M85.35%
Net income
-9.15M-967.11%
Net profit margin
-25.16-584.78%
Earnings per share
-0.20-405.81%
EBITDA
-1.74M-61.40%
Effective tax rate
5.53%
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
84.52M-17.12%
Total assets
312.16M98.35%
Total liabilities
241.75M85.77%
Total equity
70.41M
Shares outstanding
35.36M
Price to book
6.33
Return on assets
-3.76%
Return on capital
-4.27%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
-9.15M-967.11%
Cash from operations
8.70M334.27%
Cash from investing
-203.00K-3,960.00%
Cash from financing
-18.00K-100.03%
Net change in cash
8.48M-83.48%
Free cash flow
14.18M325.02%
About
Harrow Health, formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, TN. Since 2014, Harrow has started six healthcare businesses, including ImprimisRx, an ophthalmic-focused pharmaceutical company. In 2017, Harrow started and funded Eton Pharmaceuticals with a $20 million Series A financing, and Eton is now a publicly traded company. In 2017, Harrow started Surface Pharmaceuticals, hiring Dr. Kamran Hosseini to be its chief executive officer. Surface was funded with a $20 million Series A financing with Flying L Partners leading the round. In 2018, Harrow started Melt Pharmaceuticals and announced an $11 million Series A financing. In 2019, Harrow hired founder and former CEO of Doxy.me, Drew Livingston, as its Chief Innovation Officer. Livingston is the senior executive of Harrow's Visionology.com telemedicine subsidiary. Wikipedia
Founded
2012
Website
Employees
315
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu